Emactuzumab

Phase 3Monoclonal antibody

Roche

Emactuzumab is one of 42 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Giant Cell TumorActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Giant Cell TumorPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Emactuzumab

Roche

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Giant Cell Tumor

NCT05417789

Q3 2028

Phase 3Active, not recruiting

Study completion

NCT03768063

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02323191·221 enrolled

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02760797·38 enrolled

Giant Cell Tumor1 trial

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Active, not recruiting·SSynOx Therapeutics Limited·Phase 3·NCT05417789·128 enrolled

Lymphoma1 trial

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn· Roche logo

Roche·Phase 1·NCT03369964

Primary Peritoneal Cancer1 trial

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02923739·9 enrolled

Unspecified1 trial

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Emactuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emactuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emactuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Roche

Emactuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Advanced Solid Tumors2 trials

Giant Cell Tumor1 trial

Lymphoma1 trial

Primary Peritoneal Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News